Continued cemiplimab with addition of chemotherapy beyond progression in patients with advanced NSCLC on 1L cemiplimab monotherapy: 5-year outcomes of EMPOWER-Lung 1

Basit Öğe Kaydı
dc.contributor.authorGarassino, M. C.
dc.contributor.authorBaramidze, A.
dc.contributor.authorKilickap, S.
dc.contributor.authorSezer, A.
dc.contributor.authorOzguroglu, M.
dc.contributor.authorGumus, M.
dc.contributor.authorBondarenko, I.
dc.date.accessioned2025-11-16T19:35:06Z
dc.date.issued2025
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstract[Abstract Not Available]
dc.description.sponsorshipRegeneron Pharmaceuticals, Inc
dc.description.sponsorshipRegeneron Pharmaceuticals, Inc.
dc.identifier.endpageS21
dc.identifier.issn1556-0864
dc.identifier.issn1556-1380
dc.identifier.issue3
dc.identifier.startpageS19
dc.identifier.urihttps://hdl.handle.net/20.500.14730/15547
dc.identifier.volume20
dc.identifier.wosWOS:001469780300019
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherElsevier Science Inc
dc.relation.ispartofJournal of Thoracic Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.titleContinued cemiplimab with addition of chemotherapy beyond progression in patients with advanced NSCLC on 1L cemiplimab monotherapy: 5-year outcomes of EMPOWER-Lung 1
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu